Literature DB >> 34073710

Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.

Rachel-Karson Thériault1,2, Myles St-Denis1, Tristen Hewitt1,2, Jibran Y Khokhar2,3, Jasmin Lalonde1,2, Melissa L Perreault2,3.   

Abstract

Cortical circuit dysfunction is thought to be an underlying mechanism of schizophrenia (SZ) pathophysiology with normalization of aberrant circuit activity proposed as a biomarker for antipsychotic efficacy. Cannabidiol (CBD) shows potential as an adjunctive antipsychotic therapy; however, potential sex effects in these drug interactions remain unknown. In the present study, we sought to elucidate sex effects of CBD coadministration with the atypical antipsychotic iloperidone (ILO) on the activity of primary cortical neuron cultures derived from the rat methylazoxymethanol acetate (MAM) model used for the study of SZ. Spontaneous network activity measurements were obtained using a multielectrode array at baseline and following administration of CBD or ILO alone, or combined. At baseline, MAM male neurons displayed increased bursting activity whereas MAM female neurons exhibited no difference in bursting activity compared to sex-matched controls. CBD administered alone showed a rapid but transient increase in neuronal activity in the MAM networks, an effect more pronounced in females. Furthermore, ILO had an additive effect on CBD-induced elevations in activity in the MAM male neurons. In the MAM female neurons, CBD or ILO administration resulted in time-dependent elevations in neuronal activity, but the short-term CBD-induced increases in activity were lost when CBD and ILO were combined. Our findings indicate that CBD induces rapid increases in cortical neuronal activity, with sex-specific drug interactions upon ILO coadministration. This suggests that sex should be a consideration when implementing adjunct therapy for treatment of SZ.

Entities:  

Keywords:  cannabidiol; electrophysiology; haloperidol; iloperidone; primary cortical neurons; schizophrenia

Year:  2021        PMID: 34073710     DOI: 10.3390/ijms22115511

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  93 in total

1.  Working memory related gamma oscillations in schizophrenia patients.

Authors:  Canan Basar-Eroglu; Andreas Brand; Helmut Hildebrandt; Karina Karolina Kedzior; Birgit Mathes; Christina Schmiedt
Journal:  Int J Psychophysiol       Date:  2006-09-07       Impact factor: 2.997

2.  Atypical antipsychotics normalize low-gamma evoked oscillations in patients with schizophrenia.

Authors:  Manuel Alegre; Patricio Molero; Miguel Valencia; Guillermo Mayner; Felipe Ortuño; Julio Artieda
Journal:  Psychiatry Res       Date:  2016-11-26       Impact factor: 3.222

Review 3.  Men and women respond differently to antipsychotic drugs.

Authors:  Mary V Seeman
Journal:  Neuropharmacology       Date:  2019-05-08       Impact factor: 5.250

4.  Induced oscillations and the distributed cortical sources during the Wisconsin card sorting test performance in schizophrenic patients: new clues to neural connectivity.

Authors:  J A González-Hernández; I Cedeño; C Pita-Alcorta; L Galán; E Aubert; P Figueredo-Rodríguez
Journal:  Int J Psychophysiol       Date:  2003-04       Impact factor: 2.997

Review 5.  The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia.

Authors:  Kyoung-Sae Na; Han-Yong Jung; Yong-Ku Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-01       Impact factor: 5.067

6.  TNFα and IL-1β but not IL-18 Suppresses Hippocampal Long-Term Potentiation Directly at the Synapse.

Authors:  G Aleph Prieto; Liqi Tong; Erica D Smith; Carl W Cotman
Journal:  Neurochem Res       Date:  2018-04-04       Impact factor: 3.996

7.  A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Margarita M Behrens; Anthony A Grace
Journal:  J Neurosci       Date:  2009-02-25       Impact factor: 6.167

8.  Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment.

Authors:  W Löffler; R Kilian; M Toumi; M C Angermeyer
Journal:  Pharmacopsychiatry       Date:  2003-05       Impact factor: 5.788

Review 9.  Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment.

Authors:  Golam M Khandaker; Lesley Cousins; Julia Deakin; Belinda R Lennox; Robert Yolken; Peter B Jones
Journal:  Lancet Psychiatry       Date:  2015-02-25       Impact factor: 27.083

Review 10.  Understanding Cortical Dysfunction in Schizophrenia With TMS/EEG.

Authors:  Aadith Vittala; Nicholas Murphy; Atul Maheshwari; Vaishnav Krishnan
Journal:  Front Neurosci       Date:  2020-05-28       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.